Monday, July 25 KYOTO JAPAN XXIII Congress of The International Society on Thrombosis and Haemostasis Tuesday, July 26 KYOTO JAPAN XXIII Congress of The International Society on Thrombosis and Haemostasis INSIDE MAGELLAN Study MAGELLAN Study: page 1 Reducing the Risk of VTE in Acutely Ill Medical Patients Highlights from Opening Ceremony Rivaroxaban, one of a new class with rivaroxaban and the optimal diagnosed with acute heart failure, page 1 of anticoagulants, is not only duration of treatment. just under-third diagnosed with 57th Annual Meeting of effective in the treatment of deep In his presentation on Monday, acute infectious disease, and just the ISTH Scientific and vein thrombosis (DVT) but has also Alexander T. Cohen, MBBS, MSc, under one-quarter diagnosed with Standardization Committee been associated with a reduced MD, King’s College Hospital, London, acute respiratory failure. page 2 Wednesday, July 27 risk of venous thromboembolism UK, discussed results from the The two arms of the trial involved The ISTH XXIII General (VTE) in patients with acute medical multicenter, randomized, double- patients receiving either 10 mg Membership AssemblyKYOTOillness. JAPAN However, questions remain blind MAGELLAN study conducted once daily of oral rivaroxaban page 4 regarding increased bleeding risks to evaluate oral treatment with for 35 days or 40 mg once daily PreviewXXIII of Plenary Congress Lectures of The International Society on Thrombosis and Haemostasis Challenge to Novel Bioactive Peptides rivaroxaban compared with a of enoxaparin by subcutaneous - Kenji Kangawa standard 10-day treatment with injection for 10 days. Double- Recent Progress in Anticoagulant subcutaneous enoxaparin. blinding involved patients taking Therapy: Oral Direct Inhibitors of Thrombin and Factor Xa The study randomized 8,101 either 35 days of an oral placebo - Kenneth A. Bauer patients from 52 countries aged or 10 days of a placebo injection page 6 40 years or older and hospitalized accompanying the treatment ISTH Academy e-learning for an acute medical illness. assignment. Information Patients had a diverse range of The study’s primary efficacy page 12 medical conditions, with one-third (continued on page 12) Highlights from the Opening Ceremony Tuesday at a Glance More than 4,400 participants have Sunday evening. Thursday, July 28 convened in Kyoto to take part The Ceremony opened with a Ongoing in the XXIII Congress of the ISTH vibrant traditional Japanese taiko Oral Communications KYOTO2011. JAPAN Congress President Yasuo drumming performance. Audience State -of-the-Art Lectures Ikeda, MD, PhD, extended a warm members were each given a pair of SymposiaXXIII Congress of The International Society on Thrombosis and Haemostasis welcome to delegates hailing 3D glasses for a special viewing of 9:45 a.m. – 10:30 a.m. from more than 70 countries at iconic Japanese scenery, changing Plenary Lecture the official Opening Ceremony on (continued on page 12) Challenge to Novel Bioactive Peptides (K. Kangawa) Changes & Corrections in ISTH2011 Final Program 12:15p.m.-1:15p.m. O-TU-047=Withdrawn P-TU-249=Withdrawn Poster Discussion O-TU-082=INTER-INDIVIDUAL VARIABILITY IN WARFARIN DOSE P-TU-278=Withdrawn 5:15p.m.-6:00p.m. REQUIREMENT IN CHILDREN CAN BE EXPLAINED BY VKORC1 AND CYP2C9 GENOTYPE AND PATIENT CHARACTERISTICS Plenary Lecture P-TU-312=COMPETING RISK OF ATHEROSCLEROTIC RISK FACTORS FOR Elizabeth Chalmers* Recent Progress in Anticoagulation ARTERIAL AND VENOUS THROMBOSIS IN A GENERAL POPULATION. THE O-TU-142=ADAMTS13 CONTAINS TWO BINDING SITES FOR VWF TROMSO STUDY 1994-2007 Therapy (K. A. Bauer) THAT COORDINATE ENZYME-SUBSTRATE INTERACTION: AN ATOMIC John-Bjarne Hansen* FORCE MICROSCOPY STUDY P-TU-378=Withdrawn 6:15p.m.-7:45p.m. Cheng Zhu* P-TU-465=Withdrawn Technical Sessions P-TU-089=Withdrawn Satellite Symposia (GlaxoSmithKline) =Wednesday July 27, 2011 14:15 - 15:45 Satellite Symposia P-TU-107=ABNORMAL PLATELET FUNCTIONS IN TWO PATIENTS WITH FILAMIN A MUTATIONS Satellite Symposia (Loyola University Medical Center)=Wednesday July 27, Marijke Bryckaert* (FR), Eliane Berrou, Frederic Adam, Marilyne 2011 14:15 - 15:45 Lebret, Alexandre Kauskot, Martine Jandrot-Perrus, Jean-Philippe Satellite Symposia (Pfizer)=Wednesday July 27, 2011 14:15 - 15:45 ISTH2011 Congress Daily is Rosa, Cyril Goizet, Alan T. Nurden, Paquita Nurden published four times during the congress. Tuesday, July 26, 18:15 - 19:45 Industry Sponsored Satellite Symposia TIPS OF THE DAY • Join the Revolution: Advances in Oral Anticoagulation (Boehringer Ingelheim) Annex Hall 1 Exhibition open from 10:30a.m. to • Progress in Haemophilia Care: New Molecules on the Horizon (Novo Nordisk) Room A 18:00p.m. • Atypical Hemolytic Uremic Syndrome (aHUS): New Insights and Emerging Treatment Options (Alexion Obun Printing Co., Inc. Pharmaceuticals) Room B2 For a chance to win an autographed 1-17-2 Bunkyo-ku, Tokyo 113-8484 • Chronic Anticoagulation in Prevention and Treatment of VTE (Daiichi Sankyo) Room D Liverpool Football Club shirt, visit the Tel: 03-3817-5920 • Can We Predict Interventions in Haemostasis and Thrombosis? (Stago) Room E SSC 2012 booth at the entrance of the ISTH 2011 Exhibition. The ISTH 2011 Daily Congress news will also appear on the ISTH website at www.isth.org. ISTH 2011 DAILY Tuesday, July 26 57th Annual Meeting of the ISTH Scientific and Standardization Committee Anna Falanga, MD Chairman, ISTH Scientific and Standardization Committee he 57th annual meeting of ISTH. These programs reflected gave an overview and information assembled their their part of the Tof the ISTH Scientific and the SSC spirit of international on the recent advances in the program. Standardization Committee (SSC) continuous collaboration and the wide spectrum of bleeding and The growth in the SSC meetings was held prior to the start of the strong scientific involvement and thrombotic disorders, ranging from in recent years owes much to the biennial ISTH Congress, according to skill of all members to creating pathogenesis, diagnostic tools, inclusion of educational sessions. a long-lasting tradition. relevant projects aimed to respond animal models, basic research, to The multiple activities of the SSC The work of the SSC is organized in to laboratory and clinical needs finally prophylaxis and treatment. subcommittees demonstrate that 21 different subcommittees and 2 in the field of thrombosis and The main goals were to highlight the SSC is the ideal environment to working groups. They are established haemostasis. The results of several the most recent finding, but also promote the cooperation between as needed to address practical of these projects have been or provide indications useful to leading international scientists and matters related to nomenclature, will be published as Official SSC improve the capability to diagnose direct their energies to projects standards, and methods. The Communications in the JTH. precociously and treat accurately generating reliable and standardised scientific programs of each session As started in 2009 in Boston, the the various disorders of hemostasis, clinical and basic tools. presented at the 57th annual 2011 scientific program of the SSC which is of particular value to the It is desirable that more and more meeting were elegantly constructed subcommittees began with an younger colleagues that face these young investigators with an interest by the Chairmen and Co-Chairmen Educational Session, followed by topics for the first time. in thrombosis and hemostasis will of each Scientific Subcommittees the update of the ongoing scientific This year's program was very be joining the ISTH-SSC ongoing and provided an excellent activities and the proposal of new exciting, and indeed all chairs and projects and become leaders of the introduction to the main Congress ones. The Educational sessions co-chairs of the SSC masterfully future ones. SSC Reports and Recommendations 2010-2011 Animals Models intravascular coagulation. J Thromb Haemost, 8 (5): 1116–1118. Greene, T. K., Schiviz, A., Hoellriegl, W., Poncz, M., Muchitsch, E.-M. and on behalf of the Fibrinolysis Animal Models Subcommittee of the Scientific and Standardization Committee of the Longstaff, C, Rigsby, P, Whitton, C and on behalf of the SSC Subcommittee on ISTH (2010), Towards a standardization of the murine tail bleeding model. Journal of Fibrinolysis, OFFICIAL COMMUNICATION OF THE SSC: Calibration of the WHO 1st Thrombosis and Haemostasis, 8(12): 2820–2822. International Standard and SSC/ISTH Secondary Coagulation Standard for Tissue Biorheology Plasminogen Activator Antigen in Plasma. J Thromb Haemost, 8 (8): 1855–1857. Heemskerk, J. W. M., Sakariassen, K. S., Zwaginga, J. J., Brass, L. F., Jackson, S. P., Farndale, Perinatal/Pediatric Hemostasis R. W. and Biorheology Subcommittee of the SSC of the ISTH (2011), Collagen surfaces Rodeghiero, F, Tosetto, A, Abshire, T, Arnold, DM, Coller B, James, P, Neunert, C, Lillicrap, to measure thrombus formation under flow: possibilities for standardization. Journal of D and On Behalf Of The ISTH/SSC Joint vWF and Perinatal/Pediatric Hemostasis Thrombosis and Haemostasis, 9(4): 856–858. Subcommittees Working Group (2010), ISTH/SSC bleeding assessment tool: a Control of Anticoagulation standardized questionnaire and a proposal for a new bleeding score for inherited Kearon, C., Iorio, A., Palareti, G. and on behalf of the Subcommittee on Control bleeding disorders. J Thromb Haemost, 8: 2063–2065 of Anticoagulation of the SSC of the ISTH (2010), Risk of recurrent venous